GAMMA Investing
ENTA icon

GAMMA Investing’s Enanta Pharmaceuticals ENTA Stock Holding History

GAMMA Investing’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.3K Buy
1,617
+262
+19% +$3.48K ﹤0.01% 2911
2026
Q2 		$19.8K Sell
1,355
-46
-3% -$618 ﹤0.01% 2840
2026
Q1 		$17.7K Buy
1,401
+70
+5% +$938 ﹤0.01% 2774
2025
Q4 		$21K Hold
1,331
– – ﹤0.01% 2583
2025
Q3 		$15.9K Buy
1,331
+771
+138% +$6.16K ﹤0.01% 2641
2025
Q2 		$4.23K Sell
560
-762
-58% -$4.58K ﹤0.01% 3185
2025
Q1 		$7.3K Buy
+1,322
New +$8.17K ﹤0.01% 2897
2024
Q4 		– Sell
-29
Closed -$300 – 3793
2024
Q3 		$300 Sell
29
-14
-33% -$183 ﹤0.01% 3455
2024
Q2 		$558 Hold
43
– – ﹤0.01% 3193
2024
Q1 		$751 Hold
43
– – ﹤0.01% 3007
2023
Q4 		$522 Buy
+43
New +$401 ﹤0.01% 2958

Other funds holding ENTA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

GAMMA Investing's ENTA Position: Q3 2026 in Review

GAMMA Investing increased its Enanta Pharmaceuticals (ENTA) stake by 19% in Q3 2026, buying an estimated $3.48K and bringing the position to 1,617 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

GAMMA Investing first reported a position in ENTA in Q4 2023 and has held it in 11 quarters since. 11 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

  • GAMMA Investing held 1,617 shares of Enanta Pharmaceuticals worth $21.3K as of Q3 2026.
  • GAMMA Investing bought 262 Enanta Pharmaceuticals shares in Q3 2026, an estimated $3.48K.
  • Enanta Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2911 holding.
  • GAMMA Investing first reported a position in Enanta Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 11 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.